E. Monferini
Boehringer Ingelheim
18 Papers
562 Citations
E. Monferini is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Receptor & Muscarinic acetylcholine receptor. The author has an hindex of 13, co-authored 18 publications. Previous affiliations of E. Monferini include University of Milan.
Chat about Author
Papers
Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat.
TL;DR: It is proposed that these receptors may be subclassified as M2 cardiac type and M2 glandular type muscarine receptors, which are clearly distinct in the heart and exocrine glands.
378
BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
TL;DR: BIMG 80 appears to be a potential antipsychotic compound active on negative symptoms of schizophrenia with a low incidence of extrapyramidal side effects.
98
Muscarinic receptor heterogeneity in guinea pig intestinal smooth muscle: binding studies with AF-DX 116
TL;DR: The suggestion that the glandular muscarinic receptor subtype, showing a low affinity for AF-DX 116, is involved in smooth muscle contraction is suggested.
69
Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285
Aline Dumuis,Henri Gozlan,Michèle Sebben,H. Ansanay,C.A. Rizzi,Marco Turconi,E. Monferini,Ettore Giraldo,Schiantarelli Pierino,Herbert Ladinsky,Joël Bockaert +10 more
TL;DR: It is discovered that the benzimidazolone derivative DAU 6285, a search for 5-HT4 receptor antagonists, is 3–5 times more potent than tropisetron in blocking 5- HT, renzapride and BIMU 8 induced stimulation of adenylate cyclase activity in mouse embryo colliculi neurons.
65
BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.
Franco Borsini,Ettore Giraldo,E. Monferini,G. Antonini,Marco Parenti,Giuseppe Bietti,Arturo Donetti +6 more
TL;DR: It was concluded that BIMT 17 was the only compound that behaved as a full agonist with respect to the CAMP response in the cortex, while exerting concurrent agonism at 5-HT1A receptors and antagonism at5-HT2A receptors.
62